Carbon-neutral blockchain technology developer Core Scientific raised $54m from Celsius while autoimmune disease therapy developer Topas Therapeutics took a BIVF-backed round past $47m.

Funding

Celsius, the developer of a cryptocurrency yield-earning platform, supplied $54m in funding on Tuesday for Core Scientific, a US-based company that provides what it claims is a carbon-neutral blockchain infrastructure. Core Scientific had previously received $1m in equity funding in March 2018, according to a regulatory filing.

Germany-based autoimmune disease drug developer Topas Therapeutics added €18m on Tuesday from investors including pharmaceutical firm Boehringer Ingelheim to a series B round now totalling €40m ($47.1m). The corporate’s Boehringer Ingelheim Venture…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn